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REVIEW
Role of MALDI-MSI in combination with 3D tissue models for early stage efficacy 
and safety testing of drugs and toxicants
Chloe E Spencer, Lucy E Flint, Catherine J Duckett, Laura M Cole, Neil Cross, David P Smith and Malcolm R Clench
Centre for Mass Spectrometry Imaging, Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, UK
ABSTRACT
Introduction: Three-dimensional (3D) cell cultures have become increasingly important materials to 
investigate biological processes and drug efficacy and toxicity. The ability of 3D cultures to mimic the 
physiology of primary tissues and organs in the human body enables further insight into cellular 
behavior and is hence highly desirable in early-stage drug development. Analyzing the spatial distribu-
tion of drug compounds and endogenous molecules provides an insight into the efficacy of a drug 
whilst simultaneously giving information on biological responses.
Areas Covered: In this review we will examine the main 3D cell culture systems employed and 
applications, which describe their integration with mass spectrometry imaging (MSI).
Expert Opinion: MSI is a powerful technique that can map a vast range of molecules simultaneously in 
tissues without the addition of labels that can provide insights into the efficacy and safety of a new 
drug. The combination of MSI and 3D cell cultures has emerged as a promising tool in early-stage drug 
analysis. However, the most common administration route for pharmaceutical drugs is via oral delivery. 
The use of MSI in combination with models of the GI tract is an area that has been little explored to 
date, the reasons for this are discussed.
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1. Introduction
The pharmaceutical industry is currently worth in excess of 
a trillion US dollars and this value is continuously rising [1]. 
Numerous dosage forms have been designed and enhanced 
for pharmaceutical drugs that vary in administration route: 
namely oral, topical, and injection. One of the most important 
challenges during drug development is to determine if the 
administration route/dosage formulation delivers the drug to 
the required site of action. Visualizing the spatial distribution 
of endogenous and exogenous molecules within tissues pro-
vides vital information about how a therapeutic penetrates, 
distributes, and metabolizes. It can in addition allow the obser-
vation of biological responses to the treatment.
Conventional methodologies to localize molecules in tissue 
samples or in vivo include immunofluorescence microscopy 
[2], positron emission tomography (PET) [3], and magnetic 
resonance imaging (MRI) [4]. However, these methodologies 
have limitations such as requirements for the addition of 
fluorescent labels, or magnetic or isotopic probes. However, 
addition of such a probe can have an effect on therapeutic 
pathways or can alter biological compositions, and addition-
ally such probes have limited use with human subjects. Mass 
spectrometry imaging (MSI) is an established method which 
can simultaneously map a variety of molecules within a tissue, 
without the use of labels. MSI applications extend to a range 
of ionization techniques including, but not limited to, matrix- 
assisted laser desorption ionization (MALDI), desorption 
electrospray ionization (DESI), and liquid extraction surface 
analysis (LESA). MALDI-MSI is the most widely used technique 
with high spatial resolution and increasing speed of acquisi-
tion, which make it an appealing analytical method for high- 
throughput drug development studies. The multiplex nature 
of MALDI-MSI also enables the analysis of different tissue types 
and biological models for quantitative applications detecting 
a range of molecules including metabolites, lipids, peptides, 
and proteins [5–8].
The combination of MALDI-MSI with animal models has 
been demonstrated in numerous drug studies [9–13], with 
the first MS images of pharmaceutical detection achieved in 
mouse tumor and rat brain tissues in 2003 [14]. The use of 
animals in research has become prominent for drug develop-
ment due to their complex biological environment that pro-
vides a more advanced in vivo representation, modeling 
specific aspects of human diseases. Animals are therefore 
considered the ‘gold standard’ model system for the evalua-
tion of new therapeutic approaches in cancer and disease 
biology. For MALDI-MSI, methods of handling and preparing 
animal specimens have been established, from freezing and 
sectioning tissues to matrix application [15–17]. Therefore, this 
methodology is highly validated for pharmaceutical analysis. 
Progressive research has, however, challenged whether animal 
studies are an appropriate model to predict human responses 
[18]. It is strongly argued that the failure of animal models to 
replicate human conditions contributes to the failure of the 
majority of therapeutics at clinical trials [19,20]. Further 
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challenges are also raised regarding the regulatory, economic, 
and societal issues with the use of animal models 
involved [21].
There is high demand for alternative biological models that 
accurately replicate the in vivo environment and responds to 
the societal requirements to reduce animal numbers in 
research. Three-dimensional (3D) cell cultures are an 
advanced system that bridges the gap between two- 
dimensional (2D) cultures and animal models. Such an 
approach enhances the structural complexity of cellular cul-
tures so that they more closely mimic the in vivo microenvir-
onment of primary tissues. These 3D models promote levels of 
cell differentiation and tissue organization, which replicate 
typical tumor characteristics of gene and protein expression, 
nutrient diffusion, and cell-cell and cell-matrix interactions 
[22]. A variety of 3D culture models have been developed to 
meet the biological requirements for specific research includ-
ing drug analysis [23], patient-derived treatment [24], and 
biological crosstalk [25]. These models include spheroids, 
organoids, and microfluidic systems or ‘organ-on-a-chip’. 
Each model varies in their levels of complexity and yet 
requires relatively low maintenance to achieve representative 
in vivo qualities. With the additional advantages of low cost 
and high throughput, the use of 3D models is appealing for 
early-stage drug research and development prior to in vivo 
studies.
Studies which combine MSI with 3D cell culture models are 
currently of considerable interest, especially in the fields of 
drug efficacy and toxicity. The current literature in these areas 
is discussed within this review and is summarized in Table 1. 
The future potential for MSI analysis of ‘up and coming’ in vitro 
models is also discussed, identifying a gap in research regard-
ing the oral delivery administration route and modeling of the 
gastrointestinal (GI) tract. Oral delivery is the most popular 
route for administration amongst patients, and therefore its 
popularity also extends to researchers. However, analyzing the 
oral delivery route presents many challenges due to the com-
plexity of studying drug absorption in the GI tract. The 
enclosed physiology and fluctuating conditions experienced 
in the GI tract make the accurate study of oral drug absorption 
complex, which consequently hinders the progress of drug 
development [26]. From the progress of MALDI-MSI analysis 
with 3D models, and the developments of modeling the GI 
tract, it seems this combination is the next suitable direction 
for early-stage drug efficacy and toxicity studies.
2. Types of 3D cell culture models studied by MSI
2.1. Tumor spheroids
Tumor spheroids have become essential tools for in vitro 
research due to their ability to replicate the in vivo microenvir-
onment. These tumor models blend the flexibility of cell cul-
ture systems with the ability to assume complex cellular 
architecture displaying a hypoxic gradient that can be divided 
into three regions: a necrotic core, which experiences a high 
rate of apoptosis due to the extremely poor delivery of oxygen 
and nutrients; a non-proliferative region, where the cells dis-
play a state of dormancy as a result of hypoxia; and 
a proliferative edge with an abundant supply of nutrients, 
which accelerate tumor growth. The creation of spheroids 
can be achieved by a variety of means, either through inde-
pendent culture or co-culture with different cell lines, followed 
by aggregation [27]. Additionally, the use of scaffolds [28] or 
culturing with embedding gels [29] may be incorporated into 
the model.
The Hummon group were the first to publish work describ-
ing the combination of MSI with spheroids and have contin-
ued leading research utilizing spheroid cultures with MSI for 
drug analysis. Their initial study developed a colon carcinoma 
spheroid culture from the HCT 116 cell line. Li and Hummon 
[30] adapted previous MALDI-MSI protocols for imaging tissue 
sections, to examine the protein distribution within spheroids. 
To assist the handling of tumor spheroids, the group 
embedded the samples within gelatin prior to flash freezing 
and cryo-sectioning tissues at a thickness of 10 µm. A protocol 
describing the workflow of tumor spheroids with MALDI-MSI 
was published by group [31]. From the study, protein images 
of the spheroids were obtained in positive mode at a spatial 
resolution of 75 µm. MALDI-MSI was able to detect species 
within specific regions of a spheroid; with the majority of 
peaks distributed across the section, and a specific unidenti-
fied peak at m/z 12,828 localized predominantly within the 
central necrotic region. The individual peaks detected were 
not identified directly from the MSI data. Alternatively, the 
group employed an in-gel tryptic digest of the spheroids 
and identified species, including Histone H4 and Cytochrome 
C, by MALDI profiling and liquid chromatography tandem 
mass spectrometry (LC MS/MS), correlating the m/z values to 
the MSI ion maps. The detection of species localized within 
specific regions of the spheroid identified phenotypic differ-
ences that corresponded to the hypoxic gradient, therefore 
MALDI-MSI enabled a further understanding of the model. This 
was demonstrated by another study from Hiraide et al. [32], 
who utilized atmospheric pressure (AP) MALDI-MSI to charac-
terize lipids throughout spheroids and determined the species 
that are specific to cancerous tissues. The group used an MS/ 
MS imaging approach to identify m/z 885.5 as an arachidonic 
acid-containing phospholipid PI (18:0/20:4) specifically accu-
mulated in the outer edge of a colorectal cancer model. It was 
suggested this phospholipid was associated with the migra-
tion of cancer cells, which thus identified the species as 
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Table 1. Table includes a summary of literature reporting the analysis of 3D culture models with MSI discussed within review. Table is not limited to all publications 
of 3D culture models in combination with MSI.
Paper
Year 







2011 HCT 116 colon 
carcinoma
Spheroids Aggregation MALDI 75 µm MSI detected specific regional 
distributions of proteins across the 3D 
culture structures and highlighted 
a central necrotic region. Proteins 
including Histone H4 and cytochrome 






J. Vis. Exp. 
[31]
2014 HCT 116 colon 
carcinoma
Spheroids Aggregation MALDI unreported Spheroid-MSI workflow protocol. 
Includes the culture, preparation and 
analysis of spheroid samples by 
MALDI-MSI.
Hiraide et al., 
Sci. Rep. 
[32]
2016 HCT 116 & DLD-1 colon 
carcinoma. Cancer 
tissue-originated 






(AP) MALDI 5 µm laser 
spot size
Tandem MSI identified specific lipid 
species arachidonic acid containing PI 
(18:0/20:4) within the outer region in 
spheroid culture. Phospholipid 






2013 HCT 116 colon 
carcinoma
Spheroids Aggregation MALDI 75 µm Drug penetration of irinotecan mapped 
over a 72 h time-dependent course, 
moving from outer region of spheroid 
into the core. Detection of drug 






2016 HCT 116 colon 
carcinoma
Spheroids Aggregation MALDI 75 µm MSI of platinum-based drugs and their 
metabolites displayed heterogeneous 
distributions within spheroids by 







2017 HCT 116 colon 
carcinoma
Spheroids Aggregation MALDI 75 µm Demonstration of doxorubicin-encased 
liposomes delivery into spheroids. 
Detection of doxorubicin and active 
metabolites throughout spheroid by 
72 h.
Feist et al., 
Anal. Chem. 
[36]
2017 HCT 116 colon 
carcinoma
Spheroids Aggregation MALDI 75 µm Proteomic imaging of histone peptides 
and their posttranslational 
modifications determined the 
response to epigenetic drug within 
serial sections of spheroids, 
generating samples from core, the 
mid and external areas.
LaBonia et al., 
Anal. Chem. 
[37]
2018 HCT 116 colon 
carcinoma
Spheroids Aggregation MALDI 75 µm Proteomic changes from a dynamic flow 
dosing with FOLFIRI treatment 
investigated and quantified by iTRAQ 
analysis. Heterogeneous distribution 
of drugs and active metabolites 
throughout spheroid.
Liu et al., Anal. 
Chem. [38]








MALDI 70 µm On-tissue reduction and alkylation 
method to detect time-dependent 
penetration and distribution of 
monoclonal antibody, Cetuximab. 
Different localizations of immuno- 
drug determined between two cell 
lines. Detection in organoid cultures 
also demonstrated.
Flint et al., 
Anal Chem. 
[43]
2020 HCT 116 colon 
carcinoma












Characterization of a novel aggregated 
spheroid model by metabolites, 
proteins and metals determined 
phenotypic regions of the tumor 
microenvironment for pre-clinical 
applications.
Avery et al.,  
Xenobiotica 
[47]







MALDI 150 µm Demonstrated a MALDI-MSI method of 
an artificial skin model analysis by 
detection of imipramine absorption.
Francese et al., 
Anal. Chem. 
[48]




Evocutis “LabSkin” MALDI 50 µm The evaluation of curcumin as a matrix 
for MALDI across different 
applications, lung tissue, artificial skin 
and fingermark. Lipid imaging 
identified epidermis and dermis 
regions within the LSE. Detection of 
acitretin distribution within LSE.
(Continued )
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a potential biomarker for metastatic colorectal cancer. The 
identification of species in addition to its spatial distribution 
not only provides important information for understanding 
the 3D model, but also holds great value for drug distribution 
studies. This is with regard to determining therapeutic targets, 
and the penetration and localization of a drug.
The combination of spheroids with MSI has further pro-
gressed for drug developmental research. Liu et al. [33] inves-
tigated the efficacy of drug penetration by analyzing the 
spatial distribution of irinotecan, an anticancer drug, and 
topoisomerase I inhibitor, over a time-dependent course 
within HCT 116 colon carcinoma spheroids. Using MALDI-MSI 
irinotecan was observed within the necrotic core only after 
12 h of incubation. At 24 h, appreciably higher levels of the 
parent drug were observed within the central hypoxic region 
and necrotic core, and higher levels of irinotecan metabolites: 
SN-38, SN-38 glucuronide, and a decarboxylation metabolite 
were located within the outer region. This indicated that there 
was a higher activity of metabolizing enzymes in the prolif-
erative outer layer of the spheroid. In addition, high levels of 
the decarboxylated metabolite were observed by MALDI-MSI 
and these data were validated by nanoLC MS/MS; however 
quantitative analysis was not conducted. Using MALDI-MSI the 
group therefore successfully demonstrated how MSI can be 
used to locate a parent drug and its metabolites, identifying 
regions of metabolic activity within a spheroid model. This is 
highly advantageous for drug efficacy and toxicity studies for 
screening drugs, determining their targets and their half-life. 
The Hummon group has further exploited this technique to 
study the penetration of a range of drugs including platinum- 
based [34], epigenetic-targeting [35], and liposomal delivery 
[36]. LaBonia et al. [37] recently investigated the penetration of 
a combinational drug, FOLFIRI (folinic acid, 5-fluorouracil, and 
irinotecan), within HCT 116 spheroids by an innovative dosing 
platform to mimic the dynamic flow of chemotherapeutics 
used in vivo. Similar to the previous study high levels of 
metabolites within the outer proliferative region were 
observed with parent drugs, irinotecan, and folinic acid, loca-
lized within the necrotic core. Proteomic changes to the 
FOLFIRI treatment were determined by iTRAQ proteomic ana-
lysis. Protein-originated peptides labeled with iTRAQ tags 
allowed for identification of proteins in addition to quantita-
tive fold changes between treated and untreated samples, 
however spatial resolution within the spheroids was lost. This 
study provided evidence that MALDI-MSI can detect drug 
therapeutics and their metabolites within the different regions 
of the spheroid, alongside the proteomic response to treat-
ment. Not only does this support the proposition that spher-
oids display regions within the structure that mimics the 
tumor microenvironment, but it also gives valuable insights 
into the true behavior of a drug treatment in in vivo condi-
tions, which could predict clinical outcome.
Table 1. (Continued). 
Paper
Year 
Published Disease 3D Model 3D Method MSI Method
Spatial 
Resolution Summary
Harvey et al., 
Proteomics 
[49]




Innovenn “Labskin” MALDI 100 μm Absorption of acitretin within psoriatic 
LSE by MALDI-MSI determined 
a larger depth of penetration in 
psoriatic model compared to healthy 
LSE.
Russo et al., 
Anal. Chem. 
[50]




Innovenn “Labskin” MALDI 60 μm Quantitation of terbinafine 
hydrochloride absorption into 
epidermal region of LSE by MALDI- 
MSI. Regions of LSE identified by 
detection of abundant lipid species. 
Penetration enhancer DMI increased 
the concentration of drug. Validated 
by LC MS/MS.
Bergmann 




Organoid Co-culture of 
endothelial cells, 
pericytes and 
astrocytes by low- 
adhesion 
conditions.
MALDI unreported Development of a BBB organoid 
platform for drug analysis by 
fluorescent microscopy and MALDI 
MSI. Analysis of BKM120 and 
dabrafenib permeability with BBB 
organoids.
Johnson et al., 
J. Mass 
Spec. [53]
2020 Pancreatic cancer Cancer 
organoid
Patient biopsies MALDI 
Orbitrap
75 μm Method development of organoid 
cultures into geltain microarrays for 
high-throughput MSI analysis. 
Organized array of organoids in the 
same z-axis for multi-sample imaging.
Liu et al., 




2018 Colorectal cancer Cancer 
organoid
Patient biopsies MALDI 35 μm Heterogeneous distribution of 
irinotecan and its active metabolites 
within organoid cultures 
demonstrated metabolic variability in 
complex tissue samples.





2018 MCF-7 breast cancer Cancer 
organoid
Mice xenograft MALDI TOF unreported Ex vivo method of visualizing peptides 
and small molecules in breast cancer 
tumor explants as an alternative to 
spheroid cultures. Detection of small 
molecule drug (4-hydroxytamoxifen) 
and peptide drug (cyclosporin A) as 
proof-of-concept.
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From small molecule chemotherapy to immunotherapy, the 
Hummon group studied HT 29 and DLD-1 colon cancer spher-
oid cultures and patient-derived organoids to observe the dis-
tribution of cetuximab by MALDI-MSI [38]. Biopharmaceuticals 
are one of the leading growth sectors of the pharma industry, 
therefore the ability to analyze these complex molecules within 
tissues is in great demand. There are many challenges experi-
enced when protein imaging (~150 kDa), this is partly due to 
the low ionization efficiencies and reduced sensitivity [39]. Liu 
et al. [38] developed a direct on-tissue reduction with DTT 
followed by alkylation to overcome these issues. With this 
method, a protein is reduced to break the disulfide bonds 
and alkylated to prevent re-formation by modifying the 
cysteine residues. Cetuximab was therefore detected using 
a signal arising from the light chain variable domain at m/z 
23,412.5. The group observed a difference in the distribution of 
the light chain domain between the HT 29 and DLD-1 spheroid 
models; at 72 h cetuximab was primarily localized within the 
core of the HT 29 spheroids, whereas in the DLD-1 spheroids it 
was detected in the outer region. It was confirmed by immuno-
fluorescent staining that this was due to the different expres-
sion levels of the antibody target, epidermal growth factor 
receptor (EGFR) in both cell lines. The light chain domain of 
cetuximab was also detected within colorectal-tumor organoids 
at 72 h; however, information about the distribution of the 
antibody within the organoid section was not given. In addi-
tion, the study examined the treatment response by detecting 
higher intensity signals of ATP (m/z 506.0) in the core of the HT 
29 spheroids, indicating an increase in apoptosis in the pre-
sence of cetuximab. Overall, the study provided proof-of- 
concept that MALDI-MSI has the capabilities to detect the pre-
sence of a complex biopharmaceutical (150 kDa) within an 
emerging 3D in vitro model, the tumor spheroid, and analyze 
the cellular response to treatment.
It is clear from the literature that the combination of spher-
oids with MSI is a powerful tool to investigate the biological 
behavior of replicate in vitro tissues and study the efficacy of 
therapeutic drugs. Although there are a range of applications 
demonstrated, there are still gaps within the literature. As 
discussed, the main spheroid culture investigated using MSI 
has been cell-aggregated colon cancer cell lines. MALDI-MSI 
has great potential to study drug delivery in other cancer 
types such as breast or lung spheroids, which have been 
utilized in other experiments [23,40]. In addition, spheroids 
of co-cultured cell lines would provide an extra level of com-
plexity and thus possibly give data of greater clinical rele-
vance. As previously mentioned, there are various types of 
spheroids models such as those made within a biomimetic 
hydrogel scaffold, which acts to recapitulate the behavior of 
a natural extracellular matrix (ECM). An MSI experiment with 
these spheroid types could potentially provide information 
about drug behavior and biological crosstalk within the ECM, 
which is essential for certain tissue types that grow within 
a filamentous structure in vivo.
It is argued, however, that spheroid cultures are unable to 
fully recapitulate the morphological, phenotypic, and genetic 
heterogeneity of in vivo tumors [41]. This is in part due to the 
spherical shape they adopt, which does not necessarily cap-
ture the complex phenotypical structures observed in patient 
tumors, impacting how the drug behaves and penetrates the 
system. It has also been noted that spheroids of certain cell 
lines of some tumor types, e.g., breast cancer, can be difficult 
to grow large in size (<100 µm) and prove challenging for MSI 
to generate an image with sufficient raster spots to observe 
the substructure [42]. However, the continuous developments 
in MSI spatial resolution are achievable efforts to overcome 
this challenge. Although, it is an understandable requirement 
to use more advanced models that can be grown large 
enough to study the spatial distribution of molecules. For 
example, a recent study by Flint et al. [43] reported the use 
of multimodal MSI techniques: DESI, imaging mass cytometry 
(IMC) and laser ablation inductively coupled plasma (LA-ICP)- 
MS to characterize a novel aggregated 3D culture model of 
lung adenocarcinoma. The in vitro model, termed ‘aggregoid’ 
is formed via the aggregation of clonal tumor spheroids to 
create a more heterogeneous tissue of approximately 1 mm 
diameter. The molecular information of metabolites, proteins, 
and metal isotopes from the MSI techniques achieved at great 
spatial resolution had a complementary nature which enabled 
an in-depth understanding of the tumor microenvironment 
and the biological processes within the tissue model (Figure 
1). The imaging analysis of the aggregoid demonstrated 
a potential methodology for drug efficacy and toxicity studies 
within a complex tumor spheroid model that is more morpho-
logically representative.
2.2. Organoids
Derived from patient stem cells or biopsies, organoids are 
small-scale constructs that adopt the morphological struc-
tures of in vivo tumors and organs. Like spheroids, these self- 
organized systems allow for the study of biological processes 
including cell behavior, tissue repair, and drug response. As 
organoids are derived from patients, these systems hold the 
potential to assist in the prediction of drug response in 
a personalized manner. The first reported organoid structure 
dates back to 1975 by Rheinwald and Green [44], who culti-
vated a living skin replacement from epidermal keratinocytes 
which was later used to treat burn patients. Although orga-
noids first received interest back in the 1970s, within the last 
decade organoids have witnessed a revival. These systems 
have been used in a range of studies to investigate healthy 
and diseased organs or the behaviors of primary tumors to 
drug treatment. For example, Dye et al. [45], generated lung 
organoids from human pluripotent stem cells and observed 
their remarkable similarities to human fetal lungs, thus stat-
ing it an excellent model for human lung development, 
maturation, and disease studies. As a study conducted by 
Crespo et al. [46] developed colonic organoids to observe the 
blocking effects of a chemotherapeutic, geneticin in hyper-
proliferation, which has been associated with colon cancer.
Since its first development, the human skin organoid has 
been successfully commercialized by a number of businesses 
for experimental use. These include: a human reconstructed 
epidermis (HRE) and a 3D differentiated epidermis culture 
derived from human keratinocytes known as EpiSkin (Epskin, 
Lyon, France) and EpiDerm (Mattek, Ashland, USA), as well as 
full thickness living skin equivalents (LSE) that is T-skin 
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(Episkin, Lyon, France) and Labskin (Labskin UK Ltd, York, UK). 
The combination of human skin models and MALDI-MSI has 
been extensively utilized to study the drug absorption into the 
different layers of the skin. The benefits of using the skin 
models with MALDI-MSI analysis are that the skin can be 
treated similarly to animal tissues in terms of sample prepara-
tion and imaging acquisition. The earliest work of this 
approach was conducted by Avery et al. [47], who examined 
the absorption of an antidepressant drug, imipramine into 
a model of the human epidermis, ‘Straticell’. A considerable 
difference in the intensities of imipramine at 2 h and 8 h was 
observed, with higher signals of the drug in the epidermis at 
8 h. No quantifiable data analysis was conducted to achieve 
a significant concentration; however, this is partly due to the 
lack of quantitative methodologies for MALDI-MSI data at the 
time the study was conducted. Although this study stated 
some data remained inconclusive and additional experimenta-
tion is required to determine biotransformation of the drug. 
Avery et al., however, clearly understood the potential cap-
abilities of MALDI-MSI to determine drug penetration and its 
metabolizing properties.
Since this study, the analysis of LSE models by MALDI-MSI 
has been developed further for a range of drug developmen-
tal experiments. Francese et al. [48] utilized the skin model to 
investigate the effects of curcumin as a matrix to promote 
analyte ionization, with the purpose of achieving efficient 
detection of the drug acitretin in an LSE model. After 4 h 
incubation, successful penetration of acitretin within the epi-
dermis was observed by MALDI-MSI at m/z 326.4, in addition 
to analysis of several lipid species. The detected peaks from 
curcumin were compared to the peaks from the conventional 
matrix CHCA. Higher intensities with curcumin for both the 
drug and endogenous lipid species were observed indicating 
the assistance of analyte ionization. This study demonstrated 
curcumin as an extremely efficient matrix, which is vital to 
promote the higher intensities of the drug in tissues for effec-
tive detection. The following study by Harvey et al. [49] exam-
ined the absorption of the same drug, acitretin in psoriasis 
induced LSE model at longer incubation periods. It was 
demonstrated by MALDI-MSI acitretin penetrated into the 
epidermis at 24 h then further infiltrated the dermal layer of 
the skin after 48 h. To confirm the location of the drug in the 
LSE model a sodiated sphingomyelin at m/z 725.4, which 
correlated to the epidermis was detected. This time- 
dependent approach allowed for the evaluation of the drug’s 
penetration and stability properties within a living tissue. 
MALDI-MSI successfully demonstrated the capabilities of ana-
lyzing drug delivery, whilst also identifying specific regions of 
a complex organoid skin equivalent model.
The advanced technique to localize a drug within an intri-
cate model of the human skin has been further exploited to 
achieve absolute quantification by MALDI-MSI. A study con-
ducted by Russo et al. [50] developed a quantitative MSI 
(QMSI) approach to determine the amount of an antifungal 
agent, Terbinafine hydrochloride within the epidermis of the 
LSE model, ‘Labskin’. The study optimized a micro-spotting 
methodology to achieve precise and uniform analytical and 
internal standards at nanolitre volumes solely within the epi-
dermal layer, in order to mimic the cell-type ionization 
response in treated tissues. Increasing concentrations of the 
internal standard were successfully detected at m/z 148 by 
MALDI-MSI to generate a calibration curve. Signals from the 
regions of interest observed endogenous species that defined 
the epidermis (PC at m/z 184) and stratum corneum (m/z 264) 
to ensure the drug calibration signals extracted were true to 
the specified region (Figure 2). In addition, the study evaluated 
the performance of the penetration enhancer Dimethyl 
Isosorbide (DMI) added to the delivery formulation. QMSI 
Figure 1. Distribution of metabolites regulating cancer growth and survival within the HCC827 lung adenocarcinoma aggregoid central section by DESI-MSI. Ion 
density maps of metabolites outlining the core and the outer regions of the aggregoid on the image to highlight hypoxic and proliferative areas, respectively. Mean 
intensity plotted on bar graph against the core and outer regions. Scale bar 200 μm. Intermediates of the glycolysis reaction: (a) pyruvate, m/z 87.00880 and (b) 
lactate, m/z 89.02440. Glutaminolysis reaction: (c) glutamine, m/z 145.06190 and (d) glutamate, m/z 146.04590. TCA cycle: (e) citrate, m/z 191.01980; (f) malate, m/z 
133.01430; and (g) succinate, m/z 117.01940. [Flint et al., 2020, Reference [43]].
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detected an increase in concentration of Terbinafine with an 
increase in percentage of DMI within the epidermis of the LSE. 
Validation analysis observed no statistical significance 
between the values from QMSI and the values from LC MS/ 
MS, thus proving MALDI-MSI as a powerful quantitative 
method. This study demonstrated the potential impact QMSI 
with tissue engineered models will have on drug develop-
ment. By determining the amount of drug present within 
a tissue, information of its pharmacological activity can be 
obtained, in addition to observing ion suppression effects 
across varying tissues or regions within the same tissue.
The combination of MSI with tumor organoids is 
a relatively new approach. More conventional imaging tech-
niques such as fluorescence microscopy have mainly been 
used to observe these tumor models [51]. However, efforts of 
MSI strategies to analyze tumor organoids have been 
reported, either in combination with fluorescent microscopy 
to detect the penetration of small molecule drugs that are 
inherently non-fluorescent [52], or the development of sam-
ple preparation methods to improve high-throughput analy-
sis [53]. Tumor organoids are similar in size to tumor 
spheroids, and therefore require embedding medium, such 
as gelatin, to assist sample handling prior to preparation for 
MSI analysis following conventional protocols. Liu et al. [41] 
reported the use of MALDI-MSI with patient-derived color-
ectal tumor organoids (CTOs) to observe the drug distribu-
tion of irinotecan in a time-dependent dosage. MALDI-MSI 
detected high intensities of irinotecan at m/z 587.3 and its 
metabolites SN-38 (m/z 393.1) and SN-38 glucuronide (m/z 
569.2) were distributed differently within the CTOs at 24 h of 
dosage. It was stated that this was possibly due to the 
various cell types including ISCs, differentiated enterocytes, 
goblet cells, entero-endocrine cells, and Paneth cells that 
form the organ model, which could have metabolized irino-
tecan differently. Thus, supports the benefits of utilizing 
organoids over single-cell type spheroids to understand the 
metabolism of therapeutics within a structure comprised 
many cell-types. The study also employed a QMSI approach 
to determine the amount of irinotecan present in the CTOs 
compared to its metabolites at a higher dosage at 72 h, 
observing lower signal of SN-38 and indicating less conver-
sion of the active metabolite from irinotecan. This approach 
proved a valuable insight in the capabilities of QMSI to 
determine drug efficacy and potential chemo-resistance in 
patient-derived CTOs, which in turn could predict clinical 
outcome that is specific to the patient.
Alternative organoid cultures that mimic in vivo tissues 
other than skin or colorectal tumors have yet to be studied 
by MSI. Various challenges of cell culturing or MALDI-MSI 
ionization may be within optimization; however, there is pro-
gress toward the development of the MSI-organoid approach. 
For example, a study conducted by David et al. [42] developed 
a method to study tumor explants of breast cancer xenografts. 
MALDI-MSI successfully monitored the distribution of macro-
cyclic peptides and small molecule treatments ex vivo in mice 
tumors. Although the group utilized mouse tissue, the ability 
to extract biopsies and detect the uptake of therapeutics 
demonstrates a promising analytical method to examine 
patient-specific treatment for prevalent diseases such as 
breast cancer. Based on the current success, imaging analysis 
of complex organoid cultures has led to the ability to spatially 
locate and quantify drugs. This emerging technique is proving 
extremely valuable and it will be interesting to see where 
organoid imaging can take drug developmental research 
further.
Recent developments of cutting-edge technology have 
enabled further advancements with organoid cultures. 
Three-dimensional bioprinting enables fabrication of highly 
complex multi-cellular tissues by combining cells, growth 
factors, and biomimetic materials. This technology has 
Figure 2. (a) MALDI-MSI of the deuterated Terbinafine (Terbinafine-d7) source generated fragment ion in red (m/z 148) superimposed with choline headgroup in 
blue (m/z 184) and ceramide fragment peak in green (m/z 264). (b) Hematoxylin & eosin stained optical image of the sublimated section after MALDI-MSI 
(4× magnification). Calibration curve (n = 3) generated using (c) the average intensity of m/z 141 (no normalization) and (d) the ratio average intensity of m/z 141/ 
148. Normalization to the internal standard m/z 148 improved the linearity of the calibration curve. [Russo et al., 2019, Reference [50]].
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revolutionized tissue engineering due to its versatile proces-
sing capabilities to recapitulate important structural features 
of functional organs, which in the long term could be 
considered for transplantable tissue in regenerative medi-
cine [40]. Bioprinting also has the potential to be used for 
personalized medicine for cancer treatment. For example, 
Zhao et al. [41] constructed an in vitro cervical cancer model 
by the fabrication of HeLa cells with hydrogel-based materi-
als, observing a significant difference in chemo-resistance to 
the anti-cancer drug, paclitaxel, compared to 2D cell culture. 
Evaluation of anti-cancer treatment using 3D bioprinting is 
still a relatively new concept, however it has the potential 
to be used as a pre-clinical in vitro study tool in drug 
development. MSI has not been used to exploit 3D bioprint-
ing to the best of our knowledge to date, however it seems 
that this could in future be used as a valuable tool for 
in vitro drug analysis.
3. Future potential
As previously mentioned, the most common route for drug 
delivery is orally [54,55]. Oral drugs are highly convenient for 
patients and allow them to self-administer drugs without the 
assistance of a trained professional or the need for a visit to 
a hospital or clinic [54–56]. This route also boasts a high 
patient compliance, undoubtedly related to the painless and 
relatively noninvasive nature of this route in comparison to 
others such as intravenous (IV) injection, for instance [55,57]. 
Despite this, the physiologically enclosed route creates diffi-
cult challenges for drug developers and researchers. The oral 
administration route is a complex system to replicate, with 
several hollow organs that serve different purposes and there-
fore, vary in structure and environment [58,59]. Differences in 
environment exhibited within the GI tract include extreme 
fluctuation and variation in pH when moving through differ-
ent organs and the presence of acidic gastric juices [59,60]. 
Varying gastric emptying rates and phenomena such as the 
first-pass metabolism are also observed in the GI tract; all of 
these factors must be considered when creating models to 
represent the GI system as they have a substantial effect on 
the delivery and absorption of oral drugs [59,60]. Additionally, 
some drug classes also face degradation from the digestive 
enzymes present in the GI tract [57,60]. In order to develop 
and approve pharmaceutical drugs, the effect of the fluctuat-
ing environments and challenges presented by the GI tract on 
an oral drug must be greatly studied to observe and 
fully understand how their delivery will be effected prior to 
administration to a human patient. In the drug discovery and 
pre-clinical stages of drug development, human trials are 
prohibited without extensive data relating to drug safety as 
regulated by the Medicines and Healthcare products 
Regulatory Agency (MHRA) [61]. This highlights the need for 
reliable models of human physiology and specifically for orally 
administered drugs, reliable GI models with adequate means 
of quantifying the drug absorbed.
3.1. Modeling the GI Tract
The absolute gold standard for reliable oral drug studies 
would be to conduct in vivo studies on human volunteers. In 
vivo refers to an experiment which has taken place within an 
entire living organism. The most common practice for oral 
studies is to perform mass balance experiments which involve 
dosing the live participants with radiolabelled drugs [58,59]. 
The purpose of mass balance studies is ultimately to establish 
the absorption level of oral drugs in either human or animal 
participants [58,59]. The amount of radioactivity of excreta is 
quantified and compared to the radioactivity within the origi-
nal drug dosage [59]. The quantification of drug molecules 
identifiable with a radiolabel is reported to be relatively simple 
considering the complex biological environments in which it is 
found [59]. The detection and quantification of drug mole-
cules are classically established using a combination of liquid 
chromatography with radioactivity detection and on-line MS 
detection [62]. LC-MS is currently widely used for the detec-
tion, identification, and quantitation of drug metabolites from 
such mass balance studies [62]. The benefit of this particular 
mass spectrometry method provides the utmost accurate and 
sensitive quantitative information from an in vivo sample, 
giving true to life results.
Although as previously mentioned, this type of experiment 
would be prohibited in drug discovery and pre-clinical stages 
of drug development. It is also hindered by extortionate 
expenses relating to radiolabels and the price of using 
human volunteers. Such studies could be conducted on ani-
mal subjects, however as previously stated, this immediately 
creates an additional disadvantage to the technique in terms 
of the ethicality of this practice and the societal issues regard-
ing the use of animals. In the current world, the proposal and 
consequent enforcement of the Directive 76/768/EEC which 
oversees the ban of using animals for testing cosmetic pro-
ducts and ingredients have undoubtedly influenced some 
research groups in drug-related fields to move toward an 
animal-free practice [21]. Currently, there are several different 
approaches and models available that have been produced 
and developed for the study of drug absorption in the GI tract; 
they each have their own purposes and unique advantages, 
and limitations that are addressed by other models [54,58]. As 
a result, drug development tends to utilize all of these 
approaches at different stages of oral drug development 
[58]. These techniques include in situ perfusion, in-silico mod-
els, and in vitro methods. Here we evaluate the application of 
mass spectrometry techniques such models.
3.1.1. In situ perfusion
In situ perfusion is a technique that is performed within rats or 
humans whereby the subject is anesthetized, and their intest-
inal segments are cannulated and perfused with a drug solu-
tion [63,64]. The amount of drug absorbed is then calculated 
by establishing the difference between the inlet and outlet 
drug concentration [64,65]. The quantification methods that 
are routinely used in combination with in situ perfusion 
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include LC-MS/MS [63]. Intestinal perfusion within human sub-
jects is typically implemented in the later stages of drug 
development due to issues with drug safety. As with in vivo 
studies, in situ perfusion shares the issue with obtaining 
human participants for these studies [63].
In-situ perfusion of rats is typically used in pre-clinical drug 
studies and is considered the next best approach to in vivo 
studies due to the maintenance of the natural physiological 
structure and function of the GI system [66,67]. Ruiz-Picazo 
and colleagues [68] conducted a study using high- 
performance liquid chromatography (HPLC) to demonstrate 
the comparability of data obtained from their in situ perfusion 
rat model known as Doluisio. Using HPLC, the group were able 
to conclude that Doluisio was a reliable tool for predicting 
human permeability in the jejunal segment of the GI tract and 
the colon [68]. Other research groups such as Kim et al. [69], 
compared the regional absorption of the oral antihypertensive 
agent, fimasartan, in a conventional in situ single-pass perfu-
sion method with an improved in situ model. The quantitative 
assessment was made and compared using LC-MS/MS in mul-
tiple reaction monitoring mode (MRM) mode. The LC-MS/MS 
method applied by Kim and their research group was able to 
demonstrate that the improved in situ model gave a more 
accurate assessment of the fraction fimasartan that had been 
absorbed [69].
A benefit of performing in situ perfusion with rats is the 
ability to implement imaging techniques on the tissue after 
the perfusion has occurred which is not possible with humans 
due to the need for animal sacrifice. After in situ perfusion, 
drug distribution patterns are commonly imaged using tech-
niques such as PET and autoradiography [62]. There is a clear 
benefit to imaging tissue from drug absorption experiments; 
with focus on visualizing the distribution of the drug and such, 
evaluating whether a drug has reached its target. Despite this, 
the MSI methodology has not been utilized with tissue from 
in situ perfusion experiments with regard to oral drug absorp-
tion studies. Addressing the advantages of using in situ perfu-
sion models which include the ability to use biological barriers 
identical to those found in the in vivo environment, it would 
presumably make for an interesting and useful study [66,67]. 
To conduct a study combining this model with for example 
MALDI-MSI, additional steps including cryo-sectioning the tis-
sue and matrix application are conventional ways in which it 
would prepare the previously perfused tissue for analysis via 
MALDI-MSI.
A major limitation of in situ perfusion studies is the use of 
esthesia which is more invasive and of higher risk than in vivo 
mass balance studies. As consequence of this, considerably 
more funding is required to make the study more attractive to 
volunteers. Another downfall to the use of anesthesia, human, 
or animal is that when combined with surgical manipulation, it 
could have a significant effect on drug absorption rate [54,67]. 
It is essential to know how relevant an alternative model is to 
the in vivo situation, whether it be in situ or in vitro [64]. It is 
therefore important to establish an in vitro in vivo correla-
tion [58].
3.1.2. In Silico models
In vitro in vivo correlation (IVIVC) is a mathematical model that 
is used to predict and describe the relationship between 
in vitro studies and the in vivo response [26]. An in silico 
approach is commonly used to obtain an IVIVC in oral drug 
studies [59,67,70]. In this instance, in-silico refers to computer-
ized models which are used to simulate the drug absorption 
process within the GI tract. There are different in-silico models 
available ranging in complexity and their typical uses; these 
include, but are not limited to, the quantitative structure- 
activity relationship (QSAR) model and physiologically based 
pharmacokinetic (PBPK) modeling [59,67].
The purpose of mathematical models such as QSAR is to 
assess the variation in properties of a compound group and 
identify the mathematical relationship between them, if 
possible [71,72]. The QSAR model is generally limited to 
the early stages of drug development and primarily used 
to identify and exclude molecules of limited permeability 
[58,59]. Although this model can rapidly assess the relation-
ship between physiochemical properties and biopharmaceu-
tical processes, it is strictly limited by the data that is 
available from in vitro and in vivo studies, hence its limita-
tion of use [72].
Alternatively, oral PBPK models are becoming increasingly 
popular; these dynamic, mathematical models provide 
a robust in vitro – in vivo prediction and are highly sought 
after by various pharmaceutical companies at various stages of 
drug development [26,55,58]. There are a variety of PBPK 
models currently available, all are of high value in the selec-
tion and optimization of drug form and formulation stages of 
oral drug development [55,59]. The mechanistic nature of 
PBPK models is a factor that makes them much more complex 
than QSAR but allows them to incorporate physiological pro-
cesses of the gut [55]. PBPK models are built up using data 
obtained from pre-clinical in vitro data and data obtained from 
in vivo studies [26,55]. This allows the comparison, and poten-
tial validation, of in vitro studies to in vivo studies [26,55]. It 
can lead to the confirmation of a successful IVIVC between 
in vitro model to its in vivo situation; even further it can 
confirm the correlation between an animal model and 
a human in vivo study [55]. In silico approaches allow alter-
native models to compete with in vivo studies and acts as 
a tool to identify their compatibility [55].
The development and optimization of reliable oral PBPK 
models have been relatively recent. Such models have evi-
dently had an impact on the development of in situ and 
in vitro models that were previously hindered by doubt and 
speculation over their relevance to the in vivo situation. There 
are ample oral drug absorption studies performed on animal 
subjects which incorporate MSI but this is not, however, 
reflected with GI models. Therefore, the advancements in 
oral PBPK models that have allowed the in vivo relevance of 
alternative GI models to be assessed may be a factor contri-
buting to the lack of advancements in combining GI models 
with analytical methods such as MSI. The continual develop-
ment and improvements made to in silico models as discussed 
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have inevitably allowed focus to shift to evaluating and opti-
mizing alternative GI models, such as in vitro, to be more 
relevant to the in vivo situation. Hence, providing a potential 
explanation for the delay in moving to more advanced and 
novel analytical methods like QMSI which were successfully 
showcased by Russo et al. [50], in dermal drug absorption 
studies, as previously discussed.
3.1.3. In vitro methods
In-vitro methods are defined as experiments that take place 
outside of a living organism. The term, in-vitro is a broad term 
which can include either cultured cells or ex-vivo tissue [66]. 
Regardless of whether cells or tissue are used for drug absorp-
tion studies, the specimen is placed in a diffusion cell and 
intestinal absorption is assessed. As a collective, in vitro studies 
have a number of advantages in comparison to those con-
ducted in vivo; these include a significant reduction in the 
amount of drug required for the experiment and the avoid-
ance of complex surgery and animal maintenance [59]. 
Traditional in vitro methods, whether ex vivo tissue or cultured 
cells, are disadvantaged by the fact that natural physiological 
factors are not involved in the data interpretation process; for 
instance, gastric juices [63,67].
For oral drug studies, the cultured cells that are typically 
used to study and assess drug absorption include Madin- 
Darby canine kidney (MDCK) line and colorectal adenocarci-
noma (caco-2) cells, with the latter being considered a gold 
standard as well as the most established [54,66]. Each cell 
line has its own individual advantages and limitations; for 
instance, caco-2 cells can differentiate and express some 
efflux transporters, however, the lack of drug metabolizing 
P450 enzymes makes it unsuitable for the study of some drug 
classes [59]. A frequently reported analytical method used in 
combination with caco-2 cells for permeation studies is LC- 
MS/MS. Although, historically radiolabelling techniques were 
used. Lu et al. [73], recently reported the validation of an 
ultra-high-performance liquid chromatography-tandem mass 
spectrometry (UPLC-MS/MS) to quantify the amount and 
consequent intestinal permeability of the anticholinergic 
drug, Trihexyphenidyl hydrochloride, in caco-2 cells. The 
study successfully validated the method and in addition, 
gained information on the transport mechanism of that spe-
cific drug.
The use of cultured cells for in vitro experiments signifi-
cantly reduces animal usage and allows many variables to be 
explored within one experiment; ex vivo tissue used for in vitro 
experiments shares this benefit although the number of ani-
mals is not as greatly reduced [59]. Ex vivo tissue models utilize 
tissue that has been removed from a live subject although, the 
ability to explore numerous variables at once reduces the 
number of animal sacrifices required [67]. These models 
require relatively small amounts of tissue and so, allow multi-
ple experiments per animal sacrifice [59]. It would, therefore, 
be in the best interest of those especially focused on reducing 
animal testing to analyze in vitro models, with focus on ex vivo 
tissue to utilize techniques such as MSI. The ability of MSI to 
image several analytes including endogenous compounds in 
addition to drug molecules would further minimize use of 
animal subjects.
For oral drug studies, ex vivo tissue models include the 
everted gut sac technique and the Ussing chamber [59,74]. 
The everted gut sac technique is limited to the use of animal 
intestines, whereby the intestine is removed from the sacri-
ficed animal and everted over a glass rod to create an everted 
sac [59,67]. Culture medium fills the inside of the sac which is 
then sat in a vessel filled with the drug solution, allowing 
intestinal drug transport to be simulated [59]. The amount of 
drug that has accumulated inside the sac is measured and 
allows drug absorption to be quantitively assessed [59]. 
A major advantage of this technique is that it is an analytically 
simple method for the study of drug absorption as well as the 
analysis of absorption boosting excipients [66]. As with caco-2 
cells, there is a clear abundance of studies that combine the 
everted gut sac technique with LC-MS/MS for quantitative 
analysis. The combination of UPLC-MS/MS with the everted 
gut sac model has shown promise in the drug discovery 
phases with Gao et al. [75], reporting the identification and 
quantification of bioactive ingredients within Traditional 
Chinese Medicine (TCM). In this instance, the TCM was atrac-
tylode which is a dried root that is crudely extracted and orally 
taken in the form of a herbal remedy. The UPLC-MS/MS 
method was optimized for detection and quantification of 
known atractylode indicators; this method was then used to 
quantify these indicators within the everted gut model of 
a rat [75].
Unlike the Ussing chamber, there are no known publica-
tions that report the combination of the everted gut sac 
technique with MALDI-MSI. The reason for this is unknown, 
as the process needed to prepare a gut sac for MALDI-MSI 
would be indistinguishable from that for the tissue used in an 
Ussing chamber model. The Ussing chamber model works on 
a similar principle to the everted gut sac technique, however, 
the intestine is used in a sheet format rather than a sac and is 
mounted between two compartments [59,65]. The amount of 
drug that has moved from one compartment, through the 
intestinal tissue to the other compartment is then quantified, 
calculating the apparent permeability coefficients (Papp) as 
with cultured cell experiments [58,65]. In addition to drug 
absorption and permeation, bidirectional drug transport can 
also be studied using the Ussing chamber [59,76]. A major 
benefit of using ex vivo tissues in vitro is that the apical mucus 
layer remains, which makes the model more relevant to the 
in vivo situation than cultured cells which lack a mucus layer 
[67]. Although, the partial removal of the serosal muscle layer 
from epithelial tissue to complete direct permeation studies is 
reportedly a difficult task to perform [65,76].
Similarly, to the other in vitro methods, there are a vast 
amount of studies that utilize LC-MS/MS to quantify drug 
permeation and transport through the intestinal membrane. 
In addition to this, there are published studies reporting 
MALDI-MSI analysis of tissue from an Ussing chamber. 
Tanaka et al. [77], recently reported the successful use of 
MALDI-MSI to visualize oral anti-atherosclerotic dipeptides, 
Trp-His and His-Trp, rat intestinal membrane that had been 
exposed to the dipeptides in the Ussing chamber experiments. 
The MALDI-MSI analysis provided valuable information that 
one of the dipeptides faced hydrolysis at the brush border 
membranes, which would have otherwise been unknown. To 
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gain quantitative information as would be acquired using LC- 
MS/MS, QMSI is a very novel technique that could easily be 
implemented to studies such as those discussed here. QMSI 
overcomes the quantification issues usually caused by ion 
suppression effects by spotting a series of standards to create 
a calibration graph. This would allow the visualization of drug 
distribution in addition to quantitative information on the 
drug within the tissue as well as the amount that had traveled 
through the tissue.
Of all the gastrointestinal models discussed, the majority 
have adopted mass spectrometry for quantitative analysis, 
namely LC-MS/MS. Models utilizing ex vivo tissue have been 
the main source of MSI publications which have reported the 
successful mapping of oral drug distribution within tissue. In 
spite of this, drug permeation and absorption studies appear 
to fall behind in terms of advancements in mass spectrometry. 
With the previously discussed study conducted by Russo et al. 
[50], the potential to quantify drugs on an LSE tissue using 
quantitative MALDI-MSI has been clearly showcased. The 
study goes on to confirm the accuracy of their quantitative 
findings by using an LC-MS/MS method for validation. 
Although MSI has demonstrated the combination of the quan-
titative abilities of LC-MS/MS and imaging capabilities of PET, 
it has still not been used in combination with any of the 
gastrointestinal models previously discussed for oral drug 
studies.
3.2. Microfluidic systems
Similar to the in vitro model of the GI tract, microfluidic systems 
have been developed to recreate the microenvironments of 
many in vivo tissues. Although technically microfluidic systems 
mostly contain 2D cell cultures, the complex structure is 
designed to recreate the multiscale architecture and tissue- 
tissue interfaces that are crucial for organs and tissues to func-
tion. Otherwise known as ‘organ-on-a-chip’ the purpose of this 
system is not to build a whole living organ within 
a representative native environment, but rather to synthesize 
minimal functional units that recapitulate tissue and organ level 
processes. The benefits of using the microfluidic system facil-
itate the generation of microscale dimensions and volumes that 
are similar to those typically found in biological systems [78]. 
The microfluidic device can be designed in multiple ways 
depending on the complexity of the tissue that is modeled. 
The basic concept of the system is that the cells are plated 
within patterns on a chip that is coated with biocompatible 
materials such as polymer substrates. These materials allow for 
the passage of nutrients from the microchannels that provide 
a continuous flow of fluid. Unlike 2D cell cultures and 3D 
models, including spheroids and organoids, which are typically 
grown and treated sitting within a well of media. The contin-
uous flow allows for the manipulation of the chemical gradients 
for cell survival and function over a long time point. This also 
enables the treatment of drugs in a more representative man-
ner such as recapitulating the oral or IV injection administration 
route. In more complex designs, numerous microchannels are 
connected by different porous membranes for different cell 
types. This constructs the interfaces between different tissue 
types to recreate a model of the human body. The many 
attributes of microfluidic systems identify this method of cul-
ture as one of the most advanced 3D tissue-engineered models.
An extensive range of research has already utilized these 
microfluidic systems with mass spectrometry techniques in 
pharmacological studies. Santbergen et al. [79] designed an 
on-line UPLC-MS technique coupled to a ‘gut-on-a-chip’ 
model fabricated with a co-culture of colonic adenocarci-
noma cell lines, Caco-2 and HT29-MTX. The dynamic system 
had switching valves to measure the apical and basolateral 
sides of the in vitro model, allowing for permeability analysis 
of the oral drugs, verapamil, and granisetron. Qualitative and 
quantitative analysis of the anticancer drug, genistein was 
demonstrated by Chen et al. [80], by developing a stable 
isotope labeling assisted microfluidic chip electrospray (ESI)- 
MS platform. The device cultivated MCF-7 breast cancer cells 
with the tumor growth inhibitor to study cell metabolism, 
and subsequently calculated the concentration of the elut-
ing drug to determine drug absorption.
Typically, imaging organ-on-chip cultures is performed by 
either fluorescence or optical microscopy. Microfluidic 
devices may be amenable to MSI, however there is no 
literature to date that has utilized this approach. This simply 
could be due to the fact the microfluidic system is much 
more complex and lacks accessibility to image these cells. In 
addition, the sample size of the cultures in a microfluidic 
system is very small. This is a limitation for multiple reasons, 
including the inability to reproduce the spatial heterogene-
ity found in larger 3D models such as organoids. In addition 
to the spatial resolution challenges of MSI; although, the 
developments in spatial resolution technology hold poten-
tial. Air-liquid interface MSI methods such as DESI or LESA 
may be better suited with microfluidic devices as for MALDI- 
MSI required sample preparations and the laser desorption 
technique could impact the biological composition.
An unconventional approach, however, has interfaced 
a microfluidic device with MALDI-MSI. Jo et al. [81] stimulated 
neurons cultured onto a microfluidic system and collected the 
neuronal release on a functionalized surface that is compatible 
for direct MALDI-MSI analysis. An estimated amount of neuro-
peptides released including acidic peptide and α-BCP, was 
calculated by imaging the distance the peptides flowed 
through the measured channels of the functionalized surface. 
The group further adapted the MALDI-MSI method to achieve 
improved accuracy and precision [82]. This method utilized the 
abilities of MALDI-MSI to image the spatial distribution of the 
peptides as a measurement tool. Although the study did not 
directly analyze the spatial integrity of the neurons in culture, 
the group utilized the MSI method for a novel approach that 
still examined biological behavior.
As demonstrated by the extensive range of studies, 
conducted to date, MSI has proven strength in the inves-
tigation of pharmacological activity in 3D cell culture mod-
els. With the expanding surge of microfluidic systems for 
the study of therapeutics and the biological response, it 
can be contemplated that there is a high possibility the 
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MSI-microfluidics approach will be exploited within the 
foreseeable future. This is especially true when the recent 
advances in microfluidics to further enhance the complex-
ity of the 3D culture systems are considered. For example, 
macrofluidic systems or ‘organoid-on-a-chip’ platforms 
have been engineered to combine the complexity of 
microfluidic devices with ex vivo tissues or organoids, to 
replicate the in vivo microenvironments for patient-derived 
cultures [83]. For instance, our group has developed 
a macrofluidics device cultivating an ex vivo small intestine 
tissue on a Quasi Vivo 600 Liquid-Liquid Interphase in vitro 
system to model the GI tract. After treatment, the ex vivo 
tissue was removed from the fluidics system, snap frozen, 
and cryo-sectioned prior to preparing the sample with 
matrix by sublimation. MALDI-MSI analysis was able to 
detect cholesterol [Chol+H-H2O]
+ at m/z 369, observed 
throughout the tissue section (Figure 3b), and lymphatic 
tissue known as Peyer’s patches at m/z 389 identifying the 
substructures within the small intestine (Figure 3c). 
A MALDI-MS image showed the sodium adduct of the 
oral drug, atorvastatin at m/z 581 within the apical side 
of tissue after a 6-hour incubation (Figure 3d). As the 
distribution of atorvastatin is localized outside of the 
Peyer’s patches, it indicated an absorption by passive dif-
fusion (Figure 3g). Not only does this demonstrate 
advanced manipulation of ex vivo tissue, but it also allows 
for even more accurate drug analysis than previously men-
tioned 3D models such as spheroids or organoid cultures 
by MALDI-MSI. These advancements in 3D culture models 
can offer an ideal testing platform in drug developmental 
studies, which also hold potential to be exploited for ana-
lysis by MSI.
4. Conclusions
The applications described here that combine MSI with 3D cell 
culture models are just a small proportion of the published 
applications that are currently available. To date MALDI-MSI is 
the most widely used MSI technique for the study of 3D cell 
culture models. However, MALDI-MSI has well-documented 
limitations for the study of pharmaceuticals, in particular in 
the range of compounds that it is applicable to. These limita-
tions do not apply to some of the other MSI techniques 
namely DESI-MSI and the recently developed MALDI-2 techni-
que [84]. It would be therefore be expected that applications 
of MSI techniques other than MALDI-MSI will increase over the 
next period.
It is apparent from the advances made in dermal drug 
absorption studies that there is a clear opportunity for quanti-
tative MSI (however it is performed) to be used in combination 
with gastrointestinal models in a similar manner for the study 
of oral drug absorption. With the demonstrated ability of MSI 
to detect endogenous compounds such as proteins, 
a potential future area of excitement would be to combine 
quantitative MSI with other imaging techniques to study drug 
absorption within a gastrointestinal macrofluidic system.
Figure 3. Ex vivo small intestine tissue from a Quasi Vivo 600 Liquid-Liquid Interphase in vitro system. The small intestinal tissue, with the apical layer facing 
upwards, was treated with 0.5 mg/mL Atorvastatin over a 6-hour period to investigate drug absorption. (a) A scanned image of the intestinal tissue section taken 
using a Super Coolscan 5000 ED Film Scanner. (b) A MALDI-MS image showing cholesterol [Chol+H-H2O]
+ at m/z 369 in red. (c) A MALDI- MS image showing the 
Peyer’s patches at m/z 389 in blue. (d) A MALDI-MS image showing cholesterol [Chol+H-H2O]
+ at m/z 369 in red and Peyer’s patches in blue; overlapping ions are 
shown in pink. (e) A MALDI-MS image showing the sodium adduct of atorvastatin at m/z 581 in green. (f) A MALDI-MS image showing the sodium adduct of 
atorvastatin at m/z 581 in green and cholesterol [Chol+H-H2O]
+ at m/z 369 in red. (g) A MALDI-MS image showing sodium adduct of atorvastatin (m/z 581) in green 
and Peyer’s patches (m/z 389) in blue. (g) A MALDI-MS image showing the sodium adduct of atorvastatin at m/z 581 in green, cholesterol [Chol+H-H2O]
+ at m/z 369 
in red and Peyer’s patches in blue; overlapping blue and red ions are shown in pink [Credit: C. Spencer, data not published].
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5. Expert opinion
Mass spectrometry imaging (MSI) is a powerful technique that can 
map a vast range of molecules simultaneously in tissues without 
the addition of labels. Modern instruments can measure at single 
micron pixel size and at accurately and precisely quantify drugs 
ng mm−2 (of tissue area) sensitivity. For the pharmaceutical indus-
try this gives the ability to study and distinguish the distribution of 
the parent drug and its metabolites whilst simultaneously examin-
ing endogenous compounds that may be biomarkers of effect. It 
has been demonstrated in numerous studies that MSI can provide 
insights into the efficacy and safety of new drugs when used for 
both in vitro and in vivo preclinical drug trials. However, with 
regards to early-stage preclinical studies carried out using animals, 
there are increasing concerns about both the validity and morality 
of using animals in drug development experiments for drugs 
intended for humans. To address these concerns, there is interest 
in the use of 3D cell cultures, organoids, and engineered tissues 
produced using human cells for such experiments. The combina-
tion of MSI and 3D cell cultures is emerging as a promising tool in 
early-stage drug development experiment. There is an increasing 
body of work appearing in the literature describing the combina-
tion of MSI with 3D cell culture and engineered tissue. This parti-
cularly applies to drug distribution and action studies in 
experiments involving the use of tumor spheroids and tissue- 
engineered skin. Methodology for the quantitative study of drug 
distribution, drug metabolism, efficacy, and toxicity have been 
successfully demonstrated using these sample types. However, 
whilst such studies are of a great deal of interest, the most com-
mon administration route for pharmaceutical drugs is via oral 
delivery. An area of intensive study in pharma is drug absorption 
in the GI tract particularly via the small intestine. At present when 
such studies are performed in vitro using static 2D cell culture 
using permeation chamber type devices are employed. The use of 
MSI in combination with 3D models of the GI tract is an area that 
has been little explored to date. The primary barrier to develop-
ment in this area has been the lack of suitable models. However, 
reports of GI tract modeling using organoids have recently 
appeared in the literature and this can be incorporated into static 
systems. However, using 3D tissue models in combination with 
microfluidic systems creates the opportunity to generate minimal 
functional units that recapitulate tissue and organ level processes. 
Preliminary work has been carried out using microfluidic systems 
in combination with excised animal tissue and MSI in our own 
laboratory. A real opportunity for valuable future work lies in 
successful combination of GI tract models, microfluidic systems, 
and MSI and it would be expected that over the next ten years this 
combination; tissue model, microfluidic system, and MSI will find 
more and more application over and above the GI tract. This will 
both generate data more applicable to humans than animals or 2D 
cell culture and contribute to the 3Rs (reduction, refinement, and 
replacement) agenda in experiments conducted in pre-clinical 
drug development.
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